

Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study

Tom C. Russ,^{1,4*} Sarah E. Harris,⁴ G. David Batty^{1,5}

1. Alzheimer Scotland Dementia Research Centre, University of Edinburgh;
2. Edinburgh Dementia Prevention Group, University of Edinburgh;
3. Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh;
4. Lothian Birth Cohorts, Department of Psychology, University of Edinburgh;
5. UCL Research Department of Epidemiology & Public Health, University College London

* Correspondence to: Dr Tom Russ, Alzheimer Scotland Dementia Research Centre,

University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK

Telephone: +44 (0)131 650 4340; Email: T.C.Russ@ed.ac.uk

Manuscript statistics: 1000 words with one table

Funding: This article received no specific funding. The Alzheimer Scotland Dementia Research Centre is funded by Alzheimer Scotland. The Lothian Birth Cohorts are funded by Age UK. TCR is employed by the UK National Health Service and the Scottish Government. GDB is supported by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1). All researchers are independent of their funders.

Conflicts of interest: none

Author contributions: TCR and GDB conceived the study, SEH obtained and analysed the data, TCR drafted the manuscript and all authors revised it for intellectual content. TCR is the guarantor of the article.

ABSTRACT

Dementia is a major global public health concern and in addition to recognised risk factors there is emerging evidence that poorer pulmonary function is linked with subsequent dementia risk. However, it is unclear if this observed association is causal or whether it might result from confounding. Therefore, we present the first two-sample Mendelian randomisation study of the association between pulmonary function and Alzheimer dementia using the most recent genome-wide association studies to produce instrumental variables for both. We found no evidence of a causal effect of reduced Forced Expiratory Volume in 1 second (FEV_1) or Forced Vital Capacity (FVC) on Alzheimer dementia risk (both $P > 0.35$). However, the FEV_1/FVC ratio was associated with Alzheimer dementia risk with, in fact, superior function predicting an increased dementia risk ($\beta = 0.11$, $P = 0.016$) which may result from survivor bias. While we can conclude that there is no causal link between impaired pulmonary function and Alzheimer dementia, our study sheds less light on potential links with other types of dementia.

1 It is well-documented that dementia is a major and growing public health problem — the
2 number of cases are projected to increase, particularly in low-to-middle income countries.¹
3 The risk of Alzheimer disease — the most common neurodegenerative disease culminating in
4 the dementia syndrome — is thought to be raised in the presence of a relatively small series of
5 environmental and genetic factors. These include lower educational attainment,
6 hypertension, obesity, diabetes, cigarette smoking, and the *APOE* $\epsilon 4$ allele.²
7
8 Recent findings from observational studies also suggest that impaired pulmonary function is
9 consistently associated with a ~40% elevation in the risk of later dementia. While there is
10 mechanistic evidence to support this association — including the hypoxic effect of extended
11 sub-optimal ventilatory function³ — crucially, given the observational nature of these studies,
12 it is unclear if this relationship is causal.⁴ The primary impediment to drawing causal
13 inference from such observational studies is the perennial problem of confounding — the
14 notion that, in the case of pulmonary function, the characteristics of people in the low
15 functioning group differ from the unexposed in a variety of ways that may explain the
16 association. Investigators attempt to include as many relevant covariates as possible but the
17 possibility of confounding by factors which have not been measured, or imprecisely quantified,
18 is universal. Mendelian randomisation (MR) has been seen as a possible remedy to this
19 problem.⁵ This technique has been extended to a two-sample MR where genetic associations
20 for the exposure and outcome are obtained from independent samples.⁶ Accordingly, for the
21 first time to our knowledge, we present here a two-sample MR study to clarify whether our
22 original observed association between poorer pulmonary function and subsequent Alzheimer
23 dementia is causal.
24

25 METHODS

26 We ran a two-sample MR using the using summary data from the UKBiobank/SpiroMeta
27 Consortium Genome-Wide Association Study (GWAS) which comprised 400,102
28 individuals.⁷ We derived two genetic instruments for lung function: Forced Expiratory
29 Volume in one second (in litres; FEV₁) and Forced Vital Capacity (in litres; FVC). Of the
30 279 SNPs associated with lung function, only those related to the relevant trait with $P < 5 \times 10^{-8}$
31 and with the same direction of effect in UKBiobank and SpiroMeta were used as genetic
32 instruments. In addition, we included a more exploratory measure of pulmonary function —
33 the FEV₁/FVC ratio — which has been used in the diagnosis of chronic obstructive
34 pulmonary disease whereby lower values are more suggestive of this disorder.⁸ For the
35 outcome, Alzheimer dementia, we used summary data from the most recent GWAS for
36 Alzheimer dementia which included 21,982 people with Alzheimer dementia and 41,944
37 controls.⁹ The models were run in the R statistical computing environment using the
38 TwoSampleMR package.¹⁰

39

40 RESULTS

41 In **Table 1** we show the relationship between our markers of lung function with the
42 subsequent risk of Alzheimer dementia. There was no evidence of a causal effect of poorer
43 lung function —using FEV₁ or FVC — on Alzheimer dementia risk (both $P > 0.35$). However,
44 the FEV₁/FVC ratio was associated with Alzheimer dementia risk with, in fact, superior
45 function predicting an increased dementia risk ($\beta = 0.11$, $P = 0.016$). The MR Egger intercept
46 for the latter indicates little horizontal pleiotropy ($\beta = 0.0002$, $P = 0.96$) and the inverse-
47 variance weighted Q-value (177.7, $P = 0.08$) suggests no substantial heterogeneity.

48

49 DISCUSSION

50 We found that the association between lower pulmonary function and Alzheimer dementia
51 risk based on conventional epidemiological analyses was not supported as being causal in the
52 present MR analyses. Thus, it is possible that the original relationship resulted from
53 confounding by one or more unmeasured or poorly measured confounding factors. Multiple
54 candidates exist including an adverse intrauterine environment leading to reduced maximal
55 lung function, exposure to environmental factors (e.g., tobacco smoke, atmospheric
56 pollution) affecting lung function and development, and socioeconomic factors (poverty,
57 educational failure, and less-advantaged social class). In our systematic review and meta-
58 analysis, most included studies took account of smoking and cardiovascular disease risk
59 factors, and slightly fewer included height.⁴ Socioeconomic position was variably accounted
60 for and there was little coverage of the whole life course in terms of all covariables included.

61

62 The FEV₁/FVC ratio has not been routinely examined in relation to dementia risk using
63 conventional epidemiology methods.⁴ However, we found a link between high pulmonary
64 function as captured using this measure and increased Alzheimer dementia risk. This may
65 possibly be explained by survivor bias, with participants with poorer pulmonary function dying
66 before they reach late life.

67

68 MR uses genetic variants, which are randomly allocated at conception and therefore generally
69 independent of confounders that may otherwise bias the association of interest when using
70 observational methods, as proxies for environmental exposures. The approach assumes that
71 the genetic variants are: (1) associated with the exposure; (2) only associated with the
72 outcome of interest via their effect on the exposure; and 3) independent of confounders. It

73 also relies on the exposure being accurately measured in the GWAS from which the
74 instrument is derived. Pulmonary function was accurately measured with rigorous quality
75 control in UKBiobank (87.2% participants), as in the individual studies of the SpiroMeta
76 consortium.⁷ The Alzheimer dementia GWAS included 46 case-control studies from four
77 consortia.⁹ These studies used various methods of ascertaining dementia, with multiple
78 diagnostic criteria being applied and some diagnosing dementia clinically and some identifying
79 Alzheimer-type pathology post mortem. This variation is likely to affect the applicability of
80 the GWAS findings in our analysis.

81

82 In contrast to the instrumental Alzheimer dementia variable used here, most observational
83 studies use a more general category of ‘dementia.’^{4,9} This lack of clarity is common and the
84 multiple diseases which cause the dementia syndrome — such as Alzheimer disease,
85 cerebrovascular disease, Lewy body disease, and the Fronto-Temporal Lobar Degenerative
86 syndromes — are frequently conflated. Depending on the methodology used to ascertain
87 dementia status, it may be challenging to clarify an individual’s precise diagnosis. For
88 example, death certificates frequently only record the broad dementia syndrome. Thus, while
89 we can conclude that there is no causal link between impaired pulmonary function and
90 Alzheimer dementia, our study sheds less light on potential links with other types of
91 dementia. It is plausible that there may be a different relationship between pulmonary
92 function and vascular dementia, for instance.

REFERENCES

1. Prince MJ, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM. *World Alzheimer Report 2015. The Global Impact of Dementia: an analysis of prevalence, incidence, cost and trends*. London: Alzheimer's Disease International; 2015.
2. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-2734.
3. Horsburgh K, Wardlaw JM, van Agetmael T, et al. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology. *Clinical Science*. 2018;132(8):851-868.
4. Russ TC, Kivimaki M, Batty GD. Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia: A Systematic Review With Meta-analysis. *Chest*. 2020.
5. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology*. 2003;32(1):1-22.
6. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *International Journal of Epidemiology*. 2017;45(6):1717-1726.
7. Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nature Genetics*. 2019;51(3):481-493.
8. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007;176(6):532-555.
9. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nature Genetics*. 2019;51(3):414-430.
10. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genetics*. 2017;13(11):e1007081.

Table 1. Inverse-variance weighted causal effect estimates of the association between pulmonary function (FEV₁, FVC, and FEV₁/FVC ratio) and Alzheimer dementia from a two-sample Mendelian randomization

	N SNPs	β	SE	P
FEV ₁	179	0.0554	0.05989	0.354949
FVC	133	-0.01728	0.074022	0.815442
FEV ₁ /FVC ratio	154	0.113478	0.047106	0.015996